The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Losartan in Heart Failure: Hemodynamic Effects and Tolerability
Abstract
Background The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure. Methods and Results A multicenter, placebo-controlled, oral, multidose (2.5, 10, 25, and 50 mg losartan once daily) double-blind comparison in patients with symptomatic heart failure and impaired left ventricular function (ejection fraction <40%). Invasive 24-hour hemodynamic assessment was performed after the first dose and after 12 weeks of treatment. Clinical status and tolerability of treatment with losartan over the 12-week period were also evaluated. One hundred fifty-four patients were enrolled, of which 134 met the protocol criterion of baseline pulmonary capillary wedge pressure ≥13 mm Hg. During short-term administration, systemic vascular resistance (SVR) (largest reduction against placebo of 197 dyne · s−1· cm−5 at 4 hours) and blood pressure fell significantly with 50 mg, lesser decreases were seen with 25 mg, and no discernible effects were seen with 2.5 and 10 mg. After 12 weeks of treatment, similar effects were seen on SVR and blood pressure (maximal fall in SVR against placebo, 318 dyne · s−1· cm−5 at 5 hours with 50 mg). In addition, pulmonary capillary wedge pressure fell with 2.5, 25, and 50 mg (largest reduction against placebo of 6.3 mm Hg at 6 hours with 50 mg), cardiac index rose with 25 and 50 mg, and heart rate was lower with all active treatment groups. Active treatment was well tolerated, and excess cough was not reported. Conclusions This study showed that oral losartan administered to patients with symptomatic heart failure resulted in beneficial hemodynamic effects with short-term administration, with additional beneficial hemodynamic effects seen after 12 weeks of therapy. Clear effects were seen with both 25 and 50 mg, with the greatest effect seen with 50 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction
Pfeffer, M. A., Lamas, G. A., Vaughan, D. E., Parisi, A. F., & Braunwald, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807143190204 · Cited by 1,103
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
(1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 589
Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure
Packer, M., Lee, W. H., Kessler, P. D., Gottlieb, S. S., Medina, N., & Yushak, M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709243171304 · Cited by 361
Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., & DeKock, M. (1993) · Circulation · doi:10.1161/01.cir.88.4.1602 · Cited by 291
Self-citationWong, P. C., Price, W. A., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., & Timmermans, P. B. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)19984-9 · Cited by 269
Christen, Y., Waeber, B., Nussberger, J., Porchet, M., Borland, R. M., Lee, R. J., Maggon, K., Shum, L., Timmermans, P. B., & Brunner, H. R. (1991) · Circulation · doi:10.1161/01.cir.83.4.1333 · Cited by 244
Packer, M., Meller, J., Gorlin, R., & Herman, M. V. (1979) · Circulation · doi:10.1161/01.cir.59.3.531 · Cited by 241
Levine, T. B., OLIVARI, M. T., Garberg, V. R., Sharkey, S. W., & Cohn, J. N. (1984) · Circulation · doi:10.1161/01.cir.69.3.548 · Cited by 122
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Metadata
- Authors
- Crozier, I., Ikram, H., Awan, N., Cleland, J., Stephen, N., Dickstein, K., Frey, M., Young, J., Klinger, G., Makris, L., & Rucinska, E.
- Venue
- Circulation
- Published
- 1995-02
- Volume
- 91
- Issue
- 3
- Pages
- 691-697
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011909010
- Cited by
- 291
- References
- 12
- FWCI
- 25.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Losartan in Heart Failure: Hemodynamic Effects and Tolerability. https://app.cochat.ai/papers/10.1161/01.cir.91.3.691
- The paper
- Crozier, I., Ikram, H., Awan, N., Cleland, J., Stephen, N., Dickstein, K., Frey, M., Young, J., Klinger, G., Makris, L., & Rucinska, E. (1995). Losartan in Heart Failure: Hemodynamic Effects and Tolerability. Circulation. https://doi.org/10.1161/01.cir.91.3.691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.